Answers are grounded in this paper and cite their sources.
These findings confirm the presence of molecular disturbances in peripheral tissues from IBM patients and prompt patients' derived fibroblasts as a promising disease model, which may eventually be exported to other neuromuscular disorders. We additionally identify new molecular players in IBM associated with disease progression, setting the path to deepen in disease aetiology, in the identification of novel biomarkers or in the standardization of biomimetic platforms to assay new therapeutic strategies for preclinical studies.
No takes yet. Share an insight, caveat, or question.
Cantó‐Santos et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: